timothy sykes logo
ImmunityBio Receives Critical Approvals, Sees Significant Stock Gains Thumbnail
ADD US ONG Google News

ImmunityBio Receives Critical Approvals, Sees Significant Stock Gains

TIM SYKES•UPDATED MAR. 23, 2026, 11:32 AM ET
Reviewed by Jack Kellogg Fact-checked by Ellis Hobbs

ImmunityBio Inc. stocks have been trading up by 9.45 percent after announcing promising FDA designations and clinical results.

Candlestick Chart

Live Update At 11:31:48 EDT: On Monday, March 23, 2026 ImmunityBio Inc. stock [NASDAQ: IBRX] is trending up by 9.45%! Discover the key drivers behind this movement as well as our expert analysis in the detailed breakdown below.

Quick Financial Overview

The recent surge in ImmunityBio’s stock price is fueled by several remarkable advancements and approvals that have caught the financial community’s interest. In this financial overview, we delve into recent developments, spotlighting ImmunityBio’s strategies and how these are reflected in their earnings and market movements.

ImmunityBio has achieved breakthroughs in manufacturing and product approvals, significantly influencing its stock performance. Their revenues, as per the last report, stood at approximately $113.3M, denoting an impressive trajectory. Similarly, their gross margin is high at 99.3%, which is significant for a biotech firm. However, it’s important to consider that despite this, the company’s profitability metrics show negative values — negative EBIT margin (-278.4%) and profit margin (-310.18%) — indicating ongoing financial challenges typical in high-research sectors like biotech.

Their current asset turnover is modest at 0.3 times, but the current and quick ratios reflect strong liquidity positions at 5.1 and 4.6, respectively. Notably, their recent financial reports reveal substantial cash flow changes aligning with increased investment activities and product launches, signifying strategic market penetration efforts.

In recent months, ImmunityBio has reported successful completion of their NK2022 and NK2023 manufacturing programs, establishing efficient leukapheresis-based manufacturing for its NK cell therapies; this has been crucial for investor confidence. Given their strategic entry into Asian markets, especially with ANKTIVA’s approval in Macau, ImmunityBio is setting the pace for wider acceptance and leveraging of FDA and EMA precedents to expand globally.

Considering longer-term viability, analysts and shareholders must weigh these tactical victories against their long-standing financial metrics. Risks remain due to heavy expenses associated with advanced R&D, so continued investor positivity will likely rely on consistent progress reports.

Expanding Global Footprint Strengthens ImmunityBio’s Market Position

ImmunityBio’s recent market maneuvers signal a substantial expansion strategy aimed at reinforcing its global presence, particularly AGRANXTIVA’s foothold in the healthcare sector. Importantly, the addition of ANKTIVA to the National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines marks a pivot toward embracing broader clinical acceptance and even increased market share in the oncology sphere.

The March 13 completion of extensive manufacturing operations was not just a routine update. Instead, it marked the end of two crucial programs, NK2022 and NK2023, which laid a fortified path for rapid mass production of their NK cell therapy platform. Investors took note of these projects yielding nearly a 9% increase in stock, reflecting market faith in ImmunityBio’s manufacturing capacities.

Further driving investor interest, BTIG’s decision to cover ImmunityBio stock, set with a Buy rating, suggests expected stability and growth in stock value. The projected $13 price target signals optimism regarding ImmunityBio’s ANKTIVA sales, especially given its potential for more global approvals.

ImmunityBio’s first Asian approval in Macau highlights their strategy to use existing US and EU regulatory benchmarks as leverage for Asian market entry, particularly significant as the Asia-Pacific region represents a massive market with unmet oncology needs. Meanwhile, regulatory pathways there remain adaptations of US and EU experience, aiding streamlined approvals. Such expansions not only herald increased sales but nurture future commercial distributions across 34+ countries, promising for sustained growth.

More Breaking News

Conclusion

In summary, ImmunityBio’s recent strategic strides represent significant market opportunities and trader confidence bolstered by clinical achievements and territorial expansions. As the company navigates complex regulatory environments and financial constraints, these positive developments enable ImmunityBio to harness its innovations within wider healthcare frameworks.

The narrative surrounding ImmunityBio is one of technological evolution, strategic acumen, and increasing market reception. In this context, as millionaire penny stock trader and teacher Tim Sykes says, “The goal is not to win every trade but to protect your capital and keep moving forward.” Traders must continue monitoring their profitability roadmaps, as sustaining their current trajectory is essential for securing lasting success within competitive biopharmaceutical landscapes.

The market’s invigorated response reflects optimism in regulatory approvals, strategic geographic advances, and scalable production capacities—factors that indicate a promising horizon for both ImmunityBio and its traders.

This is stock news, not investment advice. Timothy Sykes News delivers real-time stock market news focused on key catalysts driving short-term price movements. Our content is tailored for active traders and investors seeking to capitalize on rapid price fluctuations, particularly in volatile sectors like penny stocks. Readers come to us for detailed coverage on earnings reports, mergers, FDA approvals, new contracts, and unusual trading volumes that can trigger significant short-term price action. Some users utilize our news to explain sudden stock movements, while others rely on it for diligent research into potential investment opportunities.

Dive deeper into the world of trading with Timothy Sykes, renowned for his expertise in penny stocks. Explore his top picks and discover the strategies that have propelled him to success with these articles:

Once you’ve got some stocks on watch, elevate your trading game with StocksToTrade the ultimate platform for traders. With specialized tools for swing and day trading, StocksToTrade will guide you through the market’s twists and turns.
Dig into StocksToTrade’s watchlists here:

How much has this post helped you?

(0 votes, average: 0 out of 5)
Leave a reply

Spot the Next Big Runner

Click Here for a Millionaire's POV on Trading IBRX

SUBSCRIBE FOR ALERTS

JOIN 50,000+ ACTIVE TRADERS

* Results are not typical and will vary from person to person. Making money trading stocks takes time, dedication, and hard work. There are inherent risks involved with investing in the stock market, including the loss of your investment. Past performance in the market is not indicative of future results. Any investment is at your own risk. See Terms of Service here

The available research on day trading suggests that most active traders lose money. Fees and overtrading are major contributors to these losses.

A 2000 study called “Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors” evaluated 66,465 U.S. households that held stocks from 1991 to 1996. The households that traded most averaged an 11.4% annual return during a period where the overall market gained 17.9%. These lower returns were attributed to overconfidence.

A 2014 paper (revised 2019) titled “Learning Fast or Slow?” analyzed the complete transaction history of the Taiwan Stock Exchange between 1992 and 2006. It looked at the ongoing performance of day traders in this sample, and found that 97% of day traders can expect to lose money from trading, and more than 90% of all day trading volume can be traced to investors who predictably lose money. Additionally, it tied the behavior of gamblers and drivers who get more speeding tickets to overtrading, and cited studies showing that legalized gambling has an inverse effect on trading volume.

A 2019 research study (revised 2020) called “Day Trading for a Living?” observed 19,646 Brazilian futures contract traders who started day trading from 2013 to 2015, and recorded two years of their trading activity. The study authors found that 97% of traders with more than 300 days actively trading lost money, and only 1.1% earned more than the Brazilian minimum wage ($16 USD per day). They hypothesized that the greater returns shown in previous studies did not differentiate between frequent day traders and those who traded rarely, and that more frequent trading activity decreases the chance of profitability.

These studies show the wide variance of the available data on day trading profitability. One thing that seems clear from the research is that most day traders lose money .

Millionaire Media 66 W Flagler St. Ste. 900 Miami, FL 33130 United States (888) 878-3621 This is for information purposes only as Millionaire Media LLC nor Timothy Sykes is registered as a securities broker-dealer or an investment adviser. No information herein is intended as securities brokerage, investment, tax, accounting or legal advice, as an offer or solicitation of an offer to sell or buy, or as an endorsement, recommendation or sponsorship of any company, security or fund. Millionaire Media LLC and Timothy Sykes cannot and does not assess, verify or guarantee the adequacy, accuracy or completeness of any information, the suitability or profitability of any particular investment, or the potential value of any investment or informational source. The reader bears responsibility for his/her own investment research and decisions, should seek the advice of a qualified securities professional before making any investment, and investigate and fully understand any and all risks before investing. Millionaire Media LLC and Timothy Sykes in no way warrants the solvency, financial condition, or investment advisability of any of the securities mentioned in communications or websites. In addition, Millionaire Media LLC and Timothy Sykes accepts no liability whatsoever for any direct or consequential loss arising from any use of this information. This information is not intended to be used as the sole basis of any investment decision, nor should it be construed as advice designed to meet the investment needs of any particular investor. Past performance is not necessarily indicative of future returns.

Citations for Disclaimer

Barber, Brad M. and Odean, Terrance, Trading is Hazardous to Your Wealth: The Common Stock Investment Performance of Individual Investors. Available at SSRN: “Day Trading for a Living?”

Barber, Brad M. and Lee, Yi-Tsung and Liu, Yu-Jane and Odean, Terrance and Zhang, Ke, Learning Fast or Slow? (May 28, 2019). Forthcoming: Review of Asset Pricing Studies, Available at SSRN: “https://ssrn.com/abstract=2535636”

Chague, Fernando and De-Losso, Rodrigo and Giovannetti, Bruno, Day Trading for a Living? (June 11, 2020). Available at SSRN: “https://ssrn.com/abstract=3423101”